Tradestie Institutional Equity Comparison Engine

EQ vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EQ Overall Edge

EQ Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against OBIO sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
EQ 1.5x vs OBIO N/M Fwd P/E
Growth & Margin Winner EQ
Op Margin 0.0% vs -195.4% ยท YoY -52.3% vs -89.4%
Momentum & Technical Winner OBIO
1Y +5.0% vs +41.2% ยท 52W Pos 9% vs 72%
Options & Structure Winner OBIO
UNCLASSIFIED (100th %ile IV) vs CONSOLIDATION (21st %ile IV)
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
1M Return -16.54%
1Y Return +4.95%
Forward P/E 1.5x
Unified AI Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
1M Return +20.29%
1Y Return +41.2%
Forward P/E N/M
Unified AI Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EQ +4.95% OBIO +41.2% Spread: +36.25 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EQ Revenue OBIO Revenue EQ Op. Margin OBIO Op. Margin Margin Edge
FY2022 $20M $0M -393.9% -924.3% EQ
FY2023 $40M $0M -40.2% -1866.2% EQ
FY2024 $40M $0M -20.1% -2437.5% EQ
FY2025 N/A $30M N/A -154.7% OBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EQ (7) vs OBIO (3)
Institutional Metric EQ OBIO Criterion Row Winner
Market Capitalization Scale $92.2M $550.9M Larger Scale OBIO
Trailing P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Forward P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Revenue Growth (YoY) Growth -52.3% -89.4% Higher Growth EQ
Operating Margin (TTM) Profitability 0.0% -195.4% Higher Margin EQ
Net Profit Margin Profitability 0.0% -182.5% Higher Margin EQ
Return on Equity (ROE) Capital Efficiency -59.0% -182.3% Higher ROE EQ
52-Week Range Position Momentum 9% ($1โ€“$4) 72% ($3โ€“$8) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.54ฮฒ ยท 89% Vol 1.18ฮฒ ยท 88% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite EQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EQ vs OBIO Buy Guide
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO CONSOLIDATION
36d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EQ nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.